Cargando…

Use of 5-Alpha-Reductase Inhibitors Did Not Increase the Risk of Cardiovascular Diseases in Patients with Benign Prostate Hyperplasia: A Five-Year Follow-Up Study

BACKGROUND: This nationwide population-based study investigated the risk of cardiovascular diseases after 5-alpha-reductase inhibitor therapy for benign prostate hyperplasia (BPH) using the National Health Insurance Research Database (NHIRD) in Taiwan. METHODS: In total, 1,486 adult patients newly d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsieh, Teng-Fu, Yang, Yu-Wan, Lee, Shang-Sen, Lin, Tien-Huang, Liu, Hsin-Ho, Tsai, Tsung-Hsun, Chen, Chi-Cheng, Huang, Yung-Sung, Lee, Ching-Chih
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372445/ https://www.ncbi.nlm.nih.gov/pubmed/25803433 http://dx.doi.org/10.1371/journal.pone.0119694

Ejemplares similares

The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
por: Kim, Eric H., et al.
Publicado: (2018)

Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia
por: Cho, Kang Jun, et al.
Publicado: (2011)

Clinical Effects of Discontinuing 5-Alpha Reductase Inhibitor in Patients With Benign Prostatic Hyperplasia
por: Kim, Won, et al.
Publicado: (2014)

Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
por: Kim, Jae Heon, et al.
Publicado: (2018)

Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia
por: Hagberg, Katrina Wilcox, et al.
Publicado: (2017)

Maximum Urine Flow Rate of Less than 15ml/Sec Increasing Risk of Urine Retention and Prostate Surgery among Patients with Alpha-1 Blockers: A 10-Year Follow Up Study
por: Liu, Hsin-Ho, et al.
Publicado: (2016)

CHADS2 scores as a predictor of ischemic stroke after radical prostatectomy
por: Yang, Yu‐Wan, et al.
Publicado: (2015)

Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer
por: Seok, Jaekwon, et al.
Publicado: (2023)

D-pinitol Inhibits Prostate Cancer Metastasis through Inhibition of αVβ3 Integrin by Modulating FAK, c-Src and NF-κB Pathways
por: Lin, Tien-Huang, et al.
Publicado: (2013)

The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).
por: Ayodele, Olulade, et al.
Publicado: (2021)

Influence of Panax ginseng on Alpha-Adrenergic Receptor of Benign Prostatic Hyperplasia
por: Kim, Su Kang, et al.
Publicado: (2014)

Berberine Improves Benign Prostatic Hyperplasia via Suppression of 5 Alpha Reductase and Extracellular Signal-Regulated Kinase in Vivo and in Vitro
por: Youn, Dong-Hyun, et al.
Publicado: (2018)

Gamma Irradiated Rhodiola sachalinensis Extract Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Downregulating 5-Alpha Reductase and Restoring Testosterone in Rats
por: Xin, Qi, et al.
Publicado: (2019)

Corrigendum: Berberine Improves Benign Prostatic Hyperplasia via Suppression of 5 Alpha Reductase and Extracellular Signal-Regulated Kinase in Vivo and in Vitro
por: Youn, Dong-Hyun, et al.
Publicado: (2019)

5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer
por: Robinson, David, et al.
Publicado: (2015)

Cinnamomi Cortex (Cinnamomum verum) Suppresses Testosterone-induced Benign Prostatic Hyperplasia by Regulating 5α-reductase
por: Choi, Hyun-Myung, et al.
Publicado: (2016)

Ethnic differences in the age-related distribution of serum prostate-specific antigen values: A study in a Taiwanese male population
por: Tsai, Tsung-Hsun, et al.
Publicado: (2023)

Pao Pereira Extract Attenuates Testosterone-Induced Benign Prostatic Hyperplasia in Rats by inhibiting 5α-Reductase
por: Liu, Jiakuan, et al.
Publicado: (2019)

Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia
por: Zhang, Jiandong, et al.
Publicado: (2023)

Efficacy and Safety of the Sandwich Method in Patients with Benign Prostate Hyperplasia: Bipolar Transurethral Resection with GreenLight Vaporization
por: Lin, Tsu-Chen, et al.
Publicado: (2022)

Combined effect of polymorphisms in type III 5-α reductase and androgen receptor gene with the risk of benign prostatic hyperplasia in Korea
por: Lee, Chung Lyul, et al.
Publicado: (2016)

α-Blocker Monotherapy and α-Blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years' Long-Term Results
por: Shin, Teak Jun, et al.
Publicado: (2012)

Cardiovascular Safety and Possible Benefit of a 5-Alpha Reductase Inhibitor among Benign Prostatic Hyperplasia Patients, A Nationally Representative Cohort of Korean Men
por: Chang, Jooyoung, et al.
Publicado: (2019)

Lower urinary tract symptoms–Benign prostatic hyperplasia may increase the risk of subsequent inguinal hernia in a Taiwanese population: A nationwide population-Based cohort study
por: Wu, Yi-Hsuan, et al.
Publicado: (2020)

Prospective Factor Analysis of Alpha Blocker Monotherapy Failure in Benign Prostatic Hyperplasia
por: Hong, Kyoung Pyo, et al.
Publicado: (2010)

Corni Fructus attenuates testosterone-induced benign prostatic hyperplasia by suppressing 5α-reductase and androgen receptor expression in rats
por: Hwangbo, Hyun, et al.
Publicado: (2018)

5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data
por: Del Giudice, Francesco, et al.
Publicado: (2023)

Prescription pattern of alpha-blockers for management of lower urinary tract symptoms/benign prostatic hyperplasia
por: Moon, Hyong Woo, et al.
Publicado: (2018)

Benign Prostatic Hyperplasia
Publicado: (2015)

Mixture of Corni Fructus and Schisandrae Fructus improves testosterone-induced benign prostatic hyperplasia through regulating 5α-reductase 2 and androgen receptor
por: Hwangbo, Hyun, et al.
Publicado: (2023)

Potential Therapeutic Roles of Tanshinone IIA in Human Bladder Cancer Cells
por: Chiu, Sheng-Chun, et al.
Publicado: (2014)

Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination
por: Shum, Cheuk Fan, et al.
Publicado: (2017)

Cynanchum wilfordii Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Regulating 5α-Reductase and Androgen Receptor Activities in a Rat Model
por: Lee, Gyuok, et al.
Publicado: (2017)

Aconiti Lateralis Radix Preparata, the Dried Root of Aconitum carmichaelii Debx., Improves Benign Prostatic Hyperplasia via Suppressing 5-Alpha Reductase and Inducing Prostate Cell Apoptosis
por: Park, Jinbong, et al.
Publicado: (2019)

A Dual 5α-Reductase Inhibitor Dutasteride Caused Reductions in Vascular Density and Area in Benign Prostatic Hyperplasia
por: Zaitsu, Masayoshi, et al.
Publicado: (2013)

Effect of 5α-reductase inhibitors on the efficiency of thulium:yttrium-aluminium-garnet (RevoLix®) vaporesection for treating benign prostatic hyperplasia
por: Chung, Jae Seung, et al.
Publicado: (2020)

Testosterone and benign prostatic hyperplasia
por: Jarvis, Thomas R, et al.
Publicado: (2015)

The effects of a Chinese herbal medicine (VGHBPH0) on patients with benign prostatic hyperplasia: A pilot study
por: Yeh, Hsin-Fu, et al.
Publicado: (2020)

Rhodobacter sphaeroides Extract Lycogen™ Attenuates Testosterone-Induced Benign Prostate Hyperplasia in Rats
por: Wang, Chiang-Ting, et al.
Publicado: (2018)

Five-Alpha Reductase Inhibitor and Breast Cancer Risk in Men: A Systematic Review
por: Kim, Min-Woo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2fqsnsqnfqpj78mudu2tjm7fst